Formulation & Process Development designed for low-dose accuracy, solubility, and stability
01
Highly Potent Compounds
What Are Highly Potent Compounds?
- Highly potent APIs are generally defined as compounds with:
- Pharmacologic activity at ≤1 mg/kg of body weight
- Occupational Exposure Limits (OELs) below 10 µg/m³
- Narrow therapeutic windows or significant toxicity risks at small doses
- Common classes include:
- Oncology agents (cytotoxics, kinase inhibitors, antibody-drug conjugate payloads)
- Hormones & steroids (e.g., contraceptives, endocrine therapies)
- CNS-active drugs (certain opioids, psychoactive compounds)
- Immunomodulators & anti-inflammatory agents (including targeted biologic-like small molecules)
CMC Pharma has supported programs across these therapeutic areas, ensuring safety, compliance, and submission-ready data.
Why Specialized Handling Matters
- HPAPIs require more than just standard lab safety. Without proper infrastructure, programs face:
- Safety Risks to laboratory staff and environment
- Cross-Contamination that can compromise study data and patient safety
- Regulatory Findings during inspections if controls are inadequate
- Timeline Delays due to lack of facility capability or rework requirements
CMC Pharma eliminates these risks with purpose-built systems and procedures for safe, compliant HPAPI development.
Safety, Containment & Compliance Protocols
- Our labs are designed and operated with HPAPI safety in mind. Key measures include:
- Dedicated containment space furnished with fume hoods, plus glove boxes
- Validated cleaning procedures to prevent cross-contamination
- Personal Protective Equipment (PPE) standards
- Chain-of-custody and batch documentation to ensure regulatory compliance and traceability
These systems ensure we can handle oncology, endocrine, CNS, and other potent molecules safely, securely, and in full alignment with regulatory expectations.
The CMC Pharma Difference
Many CDMOs claim HPAPI expertise, but their focus is often on large-scale GMP manufacturing, leaving early- and mid-stage development programs deprioritized. Some development partners or testing labs provide data in isolation without integrating regulatory foresight, leading to costly delays, rework, or compliance gaps when its time to scale up or transfer technology to a CMO.
CMC Pharma’s approach is different. We are a full-service development partner with integrated capabilities designed to advance HPAPI programs efficiently and safely:
- Development-First Focus: Our laboratory and pilot plant resources are dedicated to early- and mid-stage development, ensuring your program receives priority attention.
- Integrated Regulatory Oversight: Unlike providers that generate data without embedded regulatory insight, our regulatory experts work alongside our scientists to ensure every experiment, analytical method, and stability study produces submission-ready data. We do more than just check boxes.
- Manufacturing Enablement: We help you scale from lab bench and prepare prototypes suitable for use in animal studies. When you’re ready for large scale, we provide tech transfer services and qualify and manage CMOs equipped for HPAPI production, providing oversight for containment, process fidelity, and regulatory compliance. This seamless handoff reduces risk and prevents the inefficiencies commonly seen when development and manufacturing are handled by separate vendors.
- Therapeutic Breadth: From oncology cytotoxics to hormones, CNS-active drugs, and anti-inflammatory HPAPIs, our experience spans the key indications where highly potent compounds are most critical, delivering both scientific depth and operational expertise.
- Safety and Compliance Embedded: All projects are executed under validated containment, PPE, and chain-of-custody protocols, ensuring safety, quality, and audit readiness—even in small-scale development batches where competitors may struggle to meet strict HPAPI requirements.
Send a message
Contact Us Today and find out how CMC Pharma can help you!
Whether you need to develop robust analytical methods or require routine testing. Contact CMC Pharma to learn how we can help you advance your development program.
Send us a message or give us a call at 440-485-1734.